Study on Pirtobrutinib and Rituximab for Newly Diagnosed Marginal Zone Lymphoma

Inclusion Criteria

• Must be 18 years or older.
• Have a performance status score of 2 or less, indicating full activity or some restriction in strenuous activities.
• Have a confirmed diagnosis of marginal zone lymphoma, including specific subtypes.
• Need treatment for their lymphoma.
• No previous systemic treatment for MZL, except for certain antibiotics or antiviral therapies.
• If previously treated with local surgery or radiation, must now require systemic therapy.
• For gastric MALT lymphoma, must be negative for H. pylori or have not responded to treatment for it.
• For localized MALT lymphoma, must be ineligible for, have refused, or not responded to radiation therapy.
• Have adequate organ function, including specific blood cell counts and liver and kidney function.
• Life expectancy of more than 3 months.
• Women must not be pregnant and must meet specific criteria for menopause or use effective contraception.
• Must be able to swallow tablets.
• Must be able to understand and consent to participate in the study.

Exclusion Criteria

• Need for blood thinners like warfarin.
• Recent live-virus vaccines or need for them during the study.
• Conditions affecting the absorption of the study drug.
• History of bleeding disorders.
• Recent major surgery or not fully recovered from it.
• Another cancer that could affect participation or safety.
• Cancer spread to the central nervous system.
• Uncontrolled or significant health issues, including certain heart conditions or recent heart attacks or strokes.
• Known HIV infection.
• Active hepatitis B or C infections.
• Active cytomegalovirus infection.
• Uncontrolled autoimmune blood disorders.
• Conditions affecting the ability to understand or consent to the study.
• Severe allergy to the study drugs or their components.